NEW YORK, NY / ACCESSWIRE / July 2, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
Intersect ENT, Inc. (XENT)
Class Period: August 1, 2018 - May 6, 2019
Lead Plaintiff Deadline : July 15, 2019
Join the action: https://www.zlk.com/pslra-1/intersect-ent-inc-loss-form?prid=2209&wire=1
The lawsuit alleges: Intersect ENT, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about the Intersect ENT, Inc. class action contact firstname.lastname@example.org.
Livent Corporation (LTHM)
Class Period: on behalf of persons and entities that purchased or otherwise acquired Livent securities pursuant and/or traceable to initial public offering on or around October 11, 2018.
Lead Plaintiff Deadline : July 22, 2019
Join the action: https://www.zlk.com/pslra-1/livent-corporation-loss-form?prid=2209&wire=1
The lawsuit alleges: Livent Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) a supply contract with Nemaska Lithium Inc. had been terminated; (2) as a result, the Company would be forced to fulfill its customer contracts using alternative vendors at reduced revenues and lower margins; (3) the Company had a long-standing contract to supply lithium hydroxide to a customer at a much lower price than any of the Company's existing contracts; (4) the Company's margins were squeezed due to the customer's increased orders; and (5) as a result of the foregoing, Defendants positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To learn more about the Livent Corporation class action contact email@example.com.
Heron Therapeutics, Inc. (HRTX)
Class Period: October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline : August 5, 2019
Join the action: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?prid=2209&wire=1
The lawsuit alleges: Heron Therapeutics, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls ("CMC") and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron's NDA for HTX-011; and (iii) as a result, Heron's public statements were materially false and misleading at all relevant times.
To learn more about the Heron Therapeutics, Inc. class action contact firstname.lastname@example.org.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: